Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Contributed by: ACCESS Newswire

Logo

Tags

Healthcare & Pharmaceutical

Ripple Therapeutics

Company Update

More Like This

Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

PR Newswire associated0

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™

VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

PR Newswire associated0

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025